Results 211 to 220 of about 1,254,012 (356)

BIOM-41. GENETIC MARKERS CORRELATED WITH PROGRESSION-FREE SURVIVAL TIMES IN GLIOBLASTOMA PATIENTS UNDERGOING TREATMENT WITH TUMOR TREATING FIELDS [PDF]

, 2020
Caitlin Monson, Megan E. Tipps, Kelsey Jackson, Meghan Tierney, Nilanjana Banerji, John Trusheim   +5 more
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Dual-energy CT-based nomogram for predicting progression-free survival in locally advanced nasopharyngeal carcinoma. [PDF]

Front Oncol
Pei W, Wang C, Wei Y, Xie J, Su D, Liao H.   +5 more
europepmc   +1 more source

Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review

, 2022
Jie Zhu, Jin Tao, Zhen Dai, Yan Tan, Jiang Li, Qifeng Wang, Jinyi Lang   +6 more
openalex   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Prolonged Time From Symptoms to Diagnosis Is Associated With an Inferior Progression-Free Survival in Diffuse Large B-Cell Lymphoma. [PDF]

Cancer Med
Tokola S, Marin K, Kuusisto MEL, Kuitunen H, Pollari M, Jyrkkiö S, Suominen M, Vuolukka K, Harmanen M, Sunela K, Rönkä A, Selander T, Aromaa-Häyhä A, Ylhäinen S, Klaavuniemi T, Hakalahti A, Kuittinen O.   +16 more
europepmc   +1 more source

Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis [PDF]

Cristina Taliento, Giampaolo Morciano, Camilla Nero, Wouter Froyman, Giuseppe Vizzielli, Matteo Pavone, Stefano Salvioli, Mara Tormen, Francesco Fiorica, Gennaro Scutiero, Giovanni Scambia, Carlotta Giorgi, Pantaleo Greco, Paolo Pinton   +13 more
openalex   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Tissue and peripheral T cell receptor repertoire predicts immunotherapy response and progression-free survival in NSCLC patients. [PDF]

Sci Rep
Pino-González M, Lázaro-Quintela M, Alonso-Álvarez I, Gallardo-Gómez M, Juaneda-Magdalena L, Francisco-Fernández A, Calabuig-Fariñas S, Jantus-Lewintre E, Martínez-Fernández M.   +8 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source